For patients with serious infections, getting the right antibiotic is a time critical emergency.
Certainty that the antibiotic treatment given will be effective only comes from the best quality pathology evidence - antimicrobial susceptibility tests. Current tests can take days to return results: patients, and the doctors who care for them cannot wait that long. At Cytophenix, we’re developing the next generation of precision-personalised pathology tests: new antimicrobial susceptibility tests that deliver results in 3-5 hours, to ensure that patients receive the right treatment, at the right time, every time.
Founded in 2023 as a result of a collaboration between microbiologists, doctors, software developers, and innovators, Cytophenix is an innovative Western-Australian medtech firm focused on improving outcomes for patients with serious infections by bringing a new generation of antimicrobial susceptibility tests to market. We combine the best parts of trusted laboratory technology, revolutionary artificial intelligence, and deep understanding of the challenges posed by antimicrobial resistance to deliver new tools to combat antimicrobial resistance.
The World Health Organisation is clear: antimicrobial resistant infections kill more than 1.3 million people, and contribute to more than 5 million deaths total, every year. And it’s getting worse: if we do nothing, by 2050, resistant infections will kill more people than all other causes of death combined.
Inappropriate antimicrobial use is a key driver of the problem. Rapid and precise antimicrobial susceptibility tests are a key pillar in the response to antimicrobial resistance. Better evidence, to ensure we use the right antibiotic at the right time, is important for our society to combat the issue, but it’s more than that. For the patient experiencing a serious infection, and their family, getting an effective antibiotic as soon as possible is quite literally a matter of life and death.
Patients, and the doctors that treat them, need certainty that they are receiving the most appropriate antibiotic for their condition, and they can’t wait days to get it. At Cytophenix, we are passionate about developing innovative technological solutions to meet this need. Our mission is simple: provide doctors with the guidance they need to deliver the right treatment, at the right time, every time.
We are developing FloCAST™: a new antimicrobial susceptibility test platform. FloCAST™ provides the features end-users require: quantitative, comprehensive, phenotypic susceptibility results in just hours, not days. Using our patented technology, we start small by measuring individual bacterial or fungal cells to ensure precision. Then we go big, combining measurements from thousands to millions of cells – all measured in just a few minutes per sample – to capture even the most complex and rare mechanisms of resistance. Then we bring it all together and put that power in the hands of our users without the need for experts. Our proprietary artificial intelligence takes these complex data and returns comprehensive, completely-automated predictions of susceptibility (MIC, SIR etc.) in flexible reporting tailored to user needs.
As we progress FloCAST™ to regulatory validation and market authorization, we invite you to come with us on the journey:
Latest from the media
Cytophenix graduates from the CSIRO On Accelerate Programme 2024!
ON Accelerate programme
2023 awardees for the Raine Medical Research Foundation grants
ONCore 2023
ONAccelerate Program in 2024
